India Pharma Sees High Employee Attrition, Talent Shortage
This article was originally published in PharmAsia News
India's pharmaceutical industry has employee-attrition levels of about 30 percent, leading to staffing concerns among drug makers. Pfizer India Managing Director Kewal Handa says the attrition is due largely to poaching by companies from other industries such as financial institutions and insurance firms. Novartis Managing Director Ranjit Shahani said his company also had a shortage of talent, even at the middle levels of the firm. Novartis said its attrition rate is about 10 percent, and Pfizer says its is about 20 percent in India. (Click here for more
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.